An RNA interference (RNAi ... s drugs employ what she described as a divalent structure in which two small-interfering RNA (siRNA) duplexes are joined by a linker. This structure enable the ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

RNA interference is a conserved biological response to double ... in the interior and work outwards in contrast to canonical Dicers, which successively remove siRNA duplexes from the dsRNA termini ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Biotech stocks remain a hot sector for retail traders on Stocktwits, which collectively boast over 3.45 million followers. In ...

Atalanta Therapeutics is building on the growing attention around RNAi-based medicines with its $97 million Series B financing and plans to enter the clinic.

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company"). Atalanta, a biotechnology company based in ...

Researchers at the University of Ottawa may have cracked the code to harness both mRNA and RNAI-based therapies to ... to show delivery of both mRNA and siRNA in vivo and in vitro, to enhance ...